Recent findings revealed that hyperactivation of insulin-like growth factor (IGF) signaling was associated with reduced sensitivity to cisplatin-based chemotherapy in several types of cancers including ESCC [6],ovarian cancer [7], lung cancer [8] and mesothelioma [9]. This evidence concerns the gene IGF1 and lung carcinoma.